Study the effect of Empagliflozin in type 2 diabetic patients

To Study the effect of Empagliflozin on the Incidence of short-term major Cardiovascular events in type 2 diabetic patients with myocardial infarction requiring primary angioplasty

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210710051833N1

Enrollment

200

Registered

2022-06-22

Start date

2022-07-23

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Heart disease. Type 2 diabetes mellitus with other specified complication

Interventions

Intervention 1: Intervention group Diabetic patients who presented with myocardial infarction and received 10 mg daily ampagliflozin tablets for three months. Intervention 2: Control group: Diabetic p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients (treated with oral hypoglycemic drugs) with STEMI (typical chest pain lasting more than 30 minutes during the 12 hours prior to admission, with ST-segment elevation above 0.1 mV in both Lead or more on ECG) who will be admitted to Ayatollah Mousavi Hospital in Zanjan between August and October 1401 Diabetic patients with MI who have previously received prior treatment with metformin, sulfonylureas, or a combination of these two drugs.

Exclusion criteria

Exclusion criteria: Cardiogenic shock Hypoglycemia Diabetic ketoacidosis History of coronary artery bypass surgery Type 1 diabetes Severe liver failure Patients with advanced cancer History of severe hypersensitivity to empagliflozin or its components Severe renal failure (eGFR <30 mL / minute / 1.73 m2), end-stage renal disease (ESRD) or dialysis Hypovolemia Any inflammatory disease being treated History of any cancer Advanced heart failure

Design outcomes

Primary

Measure	Time frame
Mortality associated with cardiovascular events. Timepoint: Hospitalization time and one month and three months later. Method of measurement: Monthly face-to-face visits, tests and echoes.	—

Secondary

Measure	Time frame
Ventricular arrhythmia. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Re-infarction. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records and echo.;Need for cardiopulmonary resuscitation. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Congestive heart failure. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records and echo.;Requires revascularization of target vessels. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Stroke. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Cardiogenic shock. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.	—

Measure

Time frame

Ventricular arrhythmia. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Re-infarction. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records and echo.;Need for cardiopulmonary resuscitation. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Congestive heart failure. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records and echo.;Requires revascularization of target vessels. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Stroke. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.;Cardiogenic shock. Timepoint: Three months after hospitalization and intervention. Method of measurement: Review of patient's hospital records during three months.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Kalantari

Zanjan University of Medical Sciences

Zahra_kalantari88@yahoo.com+98 24 3552 5654

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026